Abstract
We report the design and synthesis of a series of non-nucleoside MtbTMPK inhibitors (1-14) based on the gram-positive bacterial TMPK inhibitor hit compound 1. A practical synthesis was developed to access these analogues. Several compounds show promising MtbTMPK inhibitory potency and allow the establishment of a structure-activity relationship, which is helpful for further optimization.
Keywords:
Inhibitors; Mycobacterium tuberculosis; Thymidine monophosphate kinase; Thymine derivatives; XDR-TB; extensively drug-resistant tuberculosis.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antitubercular Agents / chemical synthesis
-
Antitubercular Agents / chemistry
-
Antitubercular Agents / pharmacology*
-
Dose-Response Relationship, Drug
-
Humans
-
Microbial Sensitivity Tests
-
Models, Molecular
-
Molecular Structure
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / enzymology
-
Nucleoside-Phosphate Kinase / antagonists & inhibitors*
-
Nucleoside-Phosphate Kinase / metabolism
-
Piperidines / chemical synthesis
-
Piperidines / chemistry
-
Piperidines / pharmacology*
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Structure-Activity Relationship
Substances
-
Antitubercular Agents
-
Piperidines
-
Protein Kinase Inhibitors
-
piperidine
-
Nucleoside-Phosphate Kinase
-
dTMP kinase